NCT03968029

Brief Summary

This study will compare meniscal healing of non-vascularised area augmented or not by bone marrow injected under a protective collagen membrane (meniscal wrapping)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
96

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 18, 2017

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

May 10, 2019

Completed
20 days until next milestone

First Posted

Study publicly available on registry

May 30, 2019

Completed
5.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 19, 2025

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

March 11, 2026

Status Verified

March 1, 2026

Enrollment Period

7.7 years

First QC Date

May 10, 2019

Last Update Submit

March 10, 2026

Conditions

Outcome Measures

Primary Outcomes (5)

  • Change in integrity and healing of meniscus repair

    Arthrography (arthro-CT)

    12 and 24 months after treatment

  • Knee injury and Osteoarthritis Outcome Score (KOOS)

    Changes in the 5 subscales of KOOS as assessed from baseline to 24 months post-surgery

    baseline and 3, 12 and 24 months after treatment

  • International Knee Documentation Committee Score (IKDC)

    Change in physical pain and function as assessed by IKDC score from baseline to 24 months post-surgery

    baseline and 3, 12 and 24 months after treatment

  • SF-12 Survey

    Change in functional health and well-being as assessed by SF-12 Survey from baseline to 24 months post-surgery

    baseline and 3, 12 and 24 months after treatment

  • Failure rate

    Number of readmission for meniscus tear

    up to 24 months

Secondary Outcomes (2)

  • Change in integrity of meniscus and adjacent tissues (cartilage, bone, synovial tissue)

    12 months after treatment

  • Rate of suture type-associated complications

    up to 24 months

Study Arms (2)

Suturing meniscal augmented

EXPERIMENTAL

Non-vascularised area meniscus tear was sutured and bone marrow was injected under a protective collagen membrane (ChondroGide)

Procedure: suturing meniscal augmented

Suturing meniscal

ACTIVE COMPARATOR

Non-vascularised area meniscus tear was only sutured

Procedure: suturing meniscal

Interventions

meniscal tear sutured + bone marrow injection/collagen membrane

Also known as: meniscal wrapping
Suturing meniscal augmented

meniscal tear sutured

Suturing meniscal

Eligibility Criteria

Age15 Years - 45 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Symptomatic or traumatic tears of medial or lateral meniscus;
  • Tearing affecting: only 2/3 central (= avascular zone) over more than 1 cm OR extending from the peripheral third (= vascularized area) within the avascular zone over more than 1 cm. In this case, preservation of the peripheral third over a width of at least 4 mm from the capsule;
  • Single or multiple tears.

You may not qualify if:

  • Meniscal tears that can not be sutured, reduced / approximated
  • Tear creating a meniscal root avulsion
  • Partial meniscal tears
  • Meniscal tears already sutured
  • Cartilage damage in the compartment\> grade 2 (ICRS classification)
  • Mechanical axis (varus / valgus) ≥ 2 °
  • Untreated ligament deficiency
  • Osteotomy and / or concomitant ligament reconstruction, with the exception of ACL reconstruction.
  • Compromised general health condition (score ASA score\> 2)
  • BMI ≥30
  • Active smoking, drug use
  • Allergy to porcine collagen
  • Poor compliance

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Centre Hospitalier Universitaire Vaudois - CHUV

Lausanne, Canton of Vaud, 1011, Switzerland

Location

Dr Robin MARTIN

Lausanne, Canton of Vaud, 1011, Switzerland

Location

Study Officials

  • Robin MARTIN, MD

    Centre Hospitalier Universitaire Vaudois

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 10, 2019

First Posted

May 30, 2019

Study Start

July 18, 2017

Primary Completion

March 19, 2025

Study Completion

December 31, 2025

Last Updated

March 11, 2026

Record last verified: 2026-03

Locations